| Cat. No. |
Product |
Quantity/Size |
Price |
Data |
|
| CSB119A |
Human anti-Basigin / CD147 (Meplazumab) mAb |
100 µg |
$475.00
|
 |
BUY
|
| CSB119B |
Human anti-Basigin / CD147 (Meplazumab) mAb |
1.0 mg |
$1,395.00
|
|
BUY
|
| CSB111A |
Human anti-ERBB2 / HER2 (Trastuzumab emtansine) mAb |
100 µg |
$455.00
|
|
BUY
|
| CSB111B |
Human anti-ERBB2 / HER2 (Trastuzumab emtansine) mAb |
1.0 mg |
$1,335.00
|
|
BUY
|
| CSB112A |
Human anti-IL-17A (Ixekizumab) mAb |
100 µg |
$470.00
|
|
BUY
|
| CSB112B |
Human anti-IL-17A (Ixekizumab) mAb |
1.0 mg |
$1,375.00
|
|
BUY
|
| CSB115B |
Human anti-IL-4 Receptor Subunit alpha (Dupilumab) mAb |
1.0 mg |
$1,375.00
|
|
BUY
|
| CSB115A |
Human anti-IL-4 Receptor Subunit alpha (Dupilumab) mAb |
100 µg |
$470.00
|
|
BUY
|
| CSB113A |
Human anti-IL-6 Receptor (Sarilumab) mAb |
100 µg |
$470.00
|
|
BUY
|
| CSB113B |
Human anti-IL-6 Receptor (Sarilumab) mAb |
1.0 mg |
$1,375.00
|
|
BUY
|
| CSB120B |
Human anti-IL-6 Receptor (Tocilizumab) mAb |
1.0 mg |
$1,375.00
|
|
BUY
|
| CSB120A |
Human anti-IL-6 Receptor (Tocilizumab) mAb |
100 µg |
$470.00
|
|
BUY
|
| CSB118A |
Human anti-PD-1 (Cemiplimab) mAb |
100 µg |
$475.00
|
|
BUY
|
| CSB118B |
Human anti-PD-1 (Cemiplimab) mAb |
1.0 mg |
$1,395.00
|
|
BUY
|
| CSB114B |
Human anti-PD-1 Receptor (Nivolumab) mAb |
1.0 mg |
$1,375.00
|
|
BUY
|
| CSB114A |
Human anti-PD-1 Receptor (Nivolumab) mAb |
100 µg |
$470.00
|
|
BUY
|
| CSB116B |
Human anti-PD-1 Receptor (Pembrolizumab) mAb |
1.0 mg |
$1,375.00
|
|
BUY
|
| CSB116A |
Human anti-PD-1 Receptor (Pembrolizumab) mAb |
100 µg |
$470.00
|
|
BUY
|
| CSB117A |
Human anti-PD-L1 (Avelumab) mAb |
100 µg |
$470.00
|
|
BUY
|
| CSB117B |
Human anti-PD-L1 (Avelumab) mAb |
1.0 mg |
$1,375.00
|
|
BUY
|
| CPC534B |
Human Anti-SARS-CoV-2 Spike-RBD Bamlanivimab (LY-CoV555）Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC534A |
Human Anti-SARS-CoV-2 Spike-RBD Bamlanivimab (LY-CoV555）Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC538B |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike Glycoprotein Sotrovimab (VIR-7831 / GSK4182136) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC538A |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike Glycoprotein Sotrovimab (VIR-7831 / GSK4182136) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC535A |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike-RBD Cilgavimab (AZD1061) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC535B |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike-RBD Cilgavimab (AZD1061) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC537A |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC537B |
Human Anti-SARS-CoV-2 (2019-nCoV) Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC522A |
Human Anti-SARS-CoV-2 Spike RBD (B38) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC523B |
Human Anti-SARS-CoV-2 Spike RBD (B38) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC522B |
Human Anti-SARS-CoV-2 Spike RBD (B38) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC523A |
Human Anti-SARS-CoV-2 Spike RBD (B38) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC521A |
Human Anti-SARS-CoV-2 Spike RBD (H4) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC521B |
Human Anti-SARS-CoV-2 Spike RBD (H4) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC520A |
Human Anti-SARS-CoV-2 Spike S1 (CR3022) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC520B |
Human Anti-SARS-CoV-2 Spike S1 (CR3022) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC542C |
Human Anti-SARS-CoV-2 Spike-RBD (002-S21F2) Broad-Neutralizing mAb |
1.0 mg |
Please Inquire |
|
BUY
|
| CPC513B |
Human Anti-SARS-CoV-2 Spike-RBD (EY6A) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC513A |
Human Anti-SARS-CoV-2 Spike-RBD (EY6A) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC539C |
Human Anti-SARS-CoV-2 Spike-RBD Bebtelovimab (LY-CoV1404 / LY3853113) Neutralizing mAb |
1.0 mg |
Please Inquire |
|
BUY
|
| CPC539A |
Human Anti-SARS-CoV-2 Spike-RBD Bebtelovimab (LY-CoV1404 / LY3853113) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC539B |
Human Anti-SARS-CoV-2 Spike-RBD Bebtelovimab (LY-CoV1404 / LY3853113) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC516B |
Human Anti-SARS-CoV-2 Spike-RBD Etesevimab (CB6, JS016, LY-CoV-016) Neutralizing mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC516A |
Human Anti-SARS-CoV-2 Spike-RBD Etesevimab (CB6, JS016, LY-CoV-016) Neutralizing mAb |
50 µg |
Please Inquire |
|
BUY
|
| CPC541B |
Human Anti-SARS-CoV-2 Spike-RBD Neutralizing (S2E12) mAb |
100 µg |
Please Inquire |
|
BUY
|
| CPC541C |
Human Anti-SARS-CoV-2 Spike-RBD Neutralizing (S2E12) mAb |
1.0 mg |
Please Inquire |
|
BUY
|
| CPC541A |
Human Anti-SARS-CoV-2 Spike-RBD Neutralizing (S2E12) mAb |
50 µg |
Please Inquire |
|
BUY
|
| CMA006A |
Human anti-TNF alpha (Clone D2E7) Adalimumab |
200 μg |
$690.00
|
|
BUY
|
| CMA006B |
Human anti-TNF alpha (Clone D2E7) Adalimumab |
1.0 mg |
$2,900.00
|
|
BUY
|
| CSB104B |
Human anti-TNF alpha (Clone D2E7, Adalimumab) mAb |
1.0 mg |
$1,480.00
|
|
BUY
|
| CSB104A |
Human anti-TNF alpha (Clone D2E7, Adalimumab) mAb |
100 µg |
$500.00
|
|
BUY
|
| CSB107B |
Humanized anti-TNF alpha (Certolizumab Pegol) mAb (see DHB94401) |
1.0 mg |
Please Inquire |
|
BUY
|
| CSB107A |
Humanized anti-TNF alpha (Certolizumab Pegol) mAb (see DHB94401) |
100 µg |
Please Inquire |
|
BUY
|
| VVV02903A |
InVivoMAb Anti-HCMV/HHV5 gB Neutralizing Antibody(1G2) |
100 µg |
$475.00
|
|
BUY
|
| VVV02903B |
InVivoMAb Anti-HCMV/HHV5 gB Neutralizing Antibody(1G2) |
1.0 mg |
$1,715.00
|
|
BUY
|
| VVV02901A |
InVivoMAb Anti-HCMV/HHV5 gB Neutralizing Antibody(SM5-1) |
100 µg |
$475.00
|
|
BUY
|
| VVV02901B |
InVivoMAb Anti-HCMV/HHV5 gB Neutralizing Antibody(SM5-1) |
1.0 mg |
$1,670.00
|
|
BUY
|
| VHB63001A |
InVivoMAb Anti-Human GDF11/BMP11 (Iv0062) |
100 µg |
$475.00
|
|
BUY
|
| VHB63001B |
InVivoMAb Anti-Human GDF11/BMP11 (Iv0062) |
1 mg |
$1,715.00
|
|
BUY
|
| VHH28801A |
InVivoMAb Anti-Human IL17A (Iv0029) |
100 µg |
$475.00
|
|
BUY
|
| VHH28801B |
InVivoMAb Anti-Human IL17A (Iv0029) |
1 mg |
$1,715.00
|
|
BUY
|
| VVV07505A |
InVivoMAb Anti-MERS-CoV RBD (m336) |
100 µg |
$475.00
|
|
BUY
|
| VVV07505B |
InVivoMAb Anti-MERS-CoV RBD (m336) |
1 mg |
$1,670.00
|
|
BUY
|
| VVV08104A |
InVivoMAb Anti-Nipah virus/NiV F/Fusion glycoprotein F0 Antibody (2D3) |
100 µg |
$475.00
|
|
BUY
|
| VVV08104B |
InVivoMAb Anti-Nipah virus/NiV F/Fusion glycoprotein F0 Antibody (2D3) |
1.0 mg |
$1,670.00
|
|
BUY
|
| VVV08103A |
InVivoMAb Anti-Nipah virus/NiV Prefusion Antibody (1A9) |
100 µg |
$475.00
|
|
BUY
|
| VVV08103B |
InVivoMAb Anti-Nipah virus/NiV Prefusion Antibody (1A9) |
1.0 mg |
$1,670.00
|
|
BUY
|
| VVV08102B |
InVivoMAb Anti-Nipah virus/NiV Prefusion Antibody (1H8) |
1.0 mg |
$1,670.00
|
|
BUY
|
| VVV08102A |
InVivoMAb Anti-Nipah virus/NiV Prefusion Antibody (1H8) |
100 µg |
$475.00
|
|
BUY
|
| VVV08101B |
InVivoMAb Anti-Nipah virus/NiV Prefusion Antibody (4H3) |
1.0 mg |
$1,670.00
|
|
BUY
|
| VVV08101A |
InVivoMAb Anti-Nipah virus/NiV Prefusion Antibody (4H3) |
100 µg |
$475.00
|
|
BUY
|
| VVV08106A |
InVivoMAb Anti-Nipah virus/NiV Prefusion Protein Antibody (1H1) |
100 µg |
$475.00
|
|
BUY
|
| VVV08106B |
InVivoMAb Anti-Nipah virus/NiV Prefusion Protein Antibody (1H1) |
1.0 mg |
$1,670.00
|
|
BUY
|
| VVV08105A |
InVivoMAb Anti-Nipah virus/NiV Prefusion Protein Antibody (2B12) |
100 µg |
$475.00
|
|
BUY
|
| VVV08105B |
InVivoMAb Anti-Nipah virus/NiV Prefusion Protein Antibody (2B12) |
1.0 mg |
$1,670.00
|
|
BUY
|
| VVV00311B |
InVivoMAb Anti-SARS-CoV-2 RBD (JN.1) Neutralizing (Iv0221) |
1 mg |
$1,715.00
|
|
BUY
|
| VVV00311A |
InVivoMAb Anti-SARS-CoV-2 RBD (JN.1) Neutralizing (Iv0221) |
100 µg |
$475.00
|
|
BUY
|
| VVV00312B |
InVivoMAb Anti-SARS-CoV-2 RBD (JN.1) Neutralizing (Iv0222) |
1 mg |
$1,715.00
|
|
BUY
|
| VVV00312A |
InVivoMAb Anti-SARS-CoV-2 RBD (JN.1) Neutralizing (Iv0222) |
100 µg |
$475.00
|
|
BUY
|
| VVV00315A |
InVivoMAb Anti-SARS-CoV-2 RBD (KP.2) Neutralizing (Iv0262) |
100 µg |
$475.00
|
|
BUY
|
| VVV00315B |
InVivoMAb Anti-SARS-CoV-2 RBD (KP.2) Neutralizing (Iv0262) |
1.0 mg |
$1,715.00
|
|
BUY
|
| VVV00316A |
InVivoMAb Anti-SARS-CoV-2 RBD (KP.2) Neutralizing (Iv0263) |
100 µg |
$475.00
|
|
BUY
|
| VVV00316B |
InVivoMAb Anti-SARS-CoV-2 RBD (KP.2) Neutralizing (Iv0263) |
100 µg |
$1,715.00
|
|
BUY
|
| VVV00313B |
InVivoMAb Anti-SARS-CoV-2 RBD Neutralizing (C121) |
1.0 mg |
$1,715.00
|
|
BUY
|
| VVV00313A |
InVivoMAb Anti-SARS-CoV-2 RBD Neutralizing (C121) |
100 µg |
$475.00
|
|
BUY
|
| VVV00314A |
InVivoMAb Anti-SARS-CoV-2 RBD Neutralizing (C135) |
100 µg |
$475.00
|
|
BUY
|
| VVV00314B |
InVivoMAb Anti-SARS-CoV-2 RBD Neutralizing (C135) |
1.0 mg |
$1,715.00
|
|
BUY
|
| DHE16603A |
Research Grade Alacizumab |
100 ug |
$380.00
|
|
BUY
|
| DHE16603B |
Research Grade Alacizumab |
1.0 mg |
$1,380.00
|
|
BUY
|
| DHG52001B |
Research Grade Anetumab
|
1.0 mg |
$1,520.00
|
|
BUY
|
| DHG52001A |
Research Grade Anetumab
|
100 ug |
$420.00
|
|
BUY
|
| DFK29903B |
Research Grade Anti-Cat Allergen Fel d 1 (REGN1908) mAb |
1.0 mg |
$1,715.00
|
|
BUY
|
| DFK29903A |
Research Grade Anti-Cat Allergen Fel d 1 (REGN1908) mAb |
100µg |
$475.00
|
|
BUY
|
| DFK29904B |
Research Grade Anti-Cat Allergen Fel d 1 (REGN1909) mAb |
1.0 mg |
$1,715.00
|
|
BUY
|
| DFK29904A |
Research Grade Anti-Cat Allergen Fel d 1 (REGN1909) mAb |
100µg |
$475.00
|
|
BUY
|
| DVV03111B |
Research Grade Anti-HIV1 gp41 (10E8#) mAb |
1.0 mg |
$1,715.00
|
|
BUY
|
| DVV03111A |
Research Grade Anti-HIV1 gp41 (10E8#) mAb |
100 ug |
$475.00
|
|
BUY
|
| DHC01301B |
Research Grade Anti-Human ATTR/Transthyretin amyloidosis (NI-301) mAb |
1mg |
$1,505.00
|
|
BUY
|
| DHC01301A |
Research Grade Anti-Human ATTR/Transthyretin amyloidosis (NI-301) mAb |
100µg |
$420.00
|
|
BUY
|
| DHD34004B |
Research Grade Anti-Human CD120a/TNFRSF1A/TNFR1 (GSK2862277) |
1.0 mg |
$1,380.00
|
|
BUY
|
